190 related articles for article (PubMed ID: 24745685)
21. [Systemic mastocytosis].
Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
[TBL] [Abstract][Full Text] [Related]
22. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis.
Escribano L; Akin C; Castells M; Schwartz LB
Inflamm Allergy Drug Targets; 2006 Jan; 5(1):61-77. PubMed ID: 16613565
[TBL] [Abstract][Full Text] [Related]
23. Pathology of extramedullary mastocytosis.
Doyle LA; Hornick JL
Immunol Allergy Clin North Am; 2014 May; 34(2):323-39. PubMed ID: 24745677
[TBL] [Abstract][Full Text] [Related]
24. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.
Jordan JH; Fritsche-Polanz R; Sperr WR; Mitterbauer G; Födinger M; Schernthaner GH; Christian Bankl H; Gebhart W; Chott A; Lechner K; Valent P
Leuk Res; 2001 Jul; 25(7):627-34. PubMed ID: 11377687
[TBL] [Abstract][Full Text] [Related]
25. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
De Vita S; Schneider RK; Garcia M; Wood J; Gavillet M; Ebert BL; Gerbaulet A; Roers A; Levine RL; Mullally A; Williams DA
PLoS One; 2014; 9(5):e96209. PubMed ID: 24788138
[TBL] [Abstract][Full Text] [Related]
26. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
[TBL] [Abstract][Full Text] [Related]
27. Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.
Lang DM
Drugs Today (Barc); 2015 Jun; 51(6):367-74. PubMed ID: 26261850
[TBL] [Abstract][Full Text] [Related]
28. Update on diagnosis and treatment of mastocytosis.
Brockow K; Ring J
Curr Allergy Asthma Rep; 2011 Aug; 11(4):292-9. PubMed ID: 21523372
[TBL] [Abstract][Full Text] [Related]
29. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.
Bougherara H; Georgin-Lavialle S; Damaj G; Launay JM; Lhermitte L; Auclair C; Arock M; Dubreuil P; Hermine O; Poul MA
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):62-9. PubMed ID: 23127495
[TBL] [Abstract][Full Text] [Related]
30. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.
Bell MC; Jackson DJ
Ann Allergy Asthma Immunol; 2012 May; 108(5):383-4. PubMed ID: 22541416
[No Abstract] [Full Text] [Related]
31. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes.
Graves L; Stechschulte DJ; Morris DC; Lukert BP
J Bone Miner Res; 1990 Nov; 5(11):1113-9. PubMed ID: 2270775
[TBL] [Abstract][Full Text] [Related]
32. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
Castells M; Butterfield J
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.
Bossi G; Brazzelli V; De Amici M; Pietra D; Raviola C; Naso M; Regalbuto C; Boselli F; Fortina V; Marseglia GL
Ital J Pediatr; 2023 Jan; 49(1):6. PubMed ID: 36639823
[TBL] [Abstract][Full Text] [Related]
34. Neuropsychological features of adult mastocytosis.
Moura DS; Georgin-Lavialle S; Gaillard R; Hermine O
Immunol Allergy Clin North Am; 2014 May; 34(2):407-22. PubMed ID: 24745683
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
36. A case of neuropathic pain in monoclonal mast cell activation syndrome.
Bay JL; Sedarsky KE; Petersen MM
Ann Allergy Asthma Immunol; 2018 May; 120(5):543-544. PubMed ID: 29481890
[No Abstract] [Full Text] [Related]
37. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
38. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
39. Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis.
Peng WM; Maintz L; Allam JP; Raap U; Gütgemann I; Kirfel J; Wardelmann E; Perner S; Zhao W; Fimmers R; Walgenbach K; Oldenburg J; Schwartz LB; Novak N
Blood; 2013 Sep; 122(10):1779-88. PubMed ID: 23869086
[TBL] [Abstract][Full Text] [Related]
40. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]